Cambridge Cognition Holdings Plc announced two senior management appointments. Francesca Cormack has been appointed as the Company's Chief Scientist, having spent seven years at Cambridge Cognition, most recently as Director of Research and Innovation. Francesca will lead the Company's research and development activities and act as the Company's scientific leader, with a view to enhancing its competitive position and supporting its long-term business success.

She is also an honorary senior research fellow at Cambridge University's department of psychiatry. Jenny Barnett, currently Chief Scientific Officer, will be stepping down from the Company at the end of April 2022 to focus her efforts on Monument Therapeutics.